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Abstract A hallmark of prion diseases is the accumulation of an
abnormally folded prion protein, denoted PrPSc. Here we
describe a new and highly sensitive method for the detection of
PrPSc in brain and other tissue samples that utilizes both PrPSc
diagnostic criteria in combination; protease resistance and
aggregation. Upon filtration of tissue extracts derived from
scrapie- or bovine spongiform encephalopathy-infected animals,
PrPSc is retained and detected on the membranes. Laborious
steps such as SDS^PAGE and Western blotting are avoided with
concomitant gain in sensitivity and reliability. The new procedure
also proved useful in a screen for anti-prion compounds in a
scrapie-infected cell culture model. ß 2001 Published by Else-
vier Science B.V. on behalf of the Federation of European Bio-
chemical Societies.
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1. Introduction
The fundamental event in prion diseases such as Creutz-
feldt^Jakob disease (CJD) in humans, bovine spongiform en-
cephalopathy (BSE) in cattle and scrapie in sheep is the con-
version of the cellular prion protein, PrPC, into a pathogenic
isoform, PrPSc [1^3]. Accumulation of PrPSc in the brain of
prion-infected animals correlates with the rise in the titer of
infectious prions and is used as a diagnostic marker for prion
diseases. In light of the threat of an interspecies transmission
of BSE to humans, a large number of domestic animals must
be tested for the presence of PrPSc in the brain or other suit-
able material [4^6]. In the absence of covalent modi¢cations
that would allow a distinction between PrPSc and PrPC, PrPSc
is routinely detected in proteinase K (PK)-treated homoge-
nates by Western blotting or enzyme-linked immunosorbent
assay (ELISA) utilizing the fact that PrPSc, but not PrPC, is
partially protease resistant. Notably, these currently available
assays do not take advantage of the fact that PrPSc forms
aggregates. Indeed, formation of detergent-resistant PrP ag-
gregates is a general biochemical property of PrPSc, even for
rare prion strains where PrPSc is sensitive to proteolytic diges-
tion [7].
As shown previously, detection of amyloid aggregates in
neurodegenerative diseases caused by polyglutamine proteins
is possible by a simple ¢lter retention assay [8]. Here we de-
veloped a similar technique for the reliable and sensitive de-
tection of PrPSc in tissue homogenates or cell lysates using a
slot blot device and nitrocellulose (NC) or cellulose acetate
(CA) membranes. With adaptation, this method will allow the
rapid high-throughput testing of large numbers of tissue sam-
ples for PrPSc and the screening of compound libraries for
substances with anti-prion activity.
2. Materials and methods
2.1. Preparation of protein extracts
2.1.1. Mouse brain. Whole brains derived from CD1 mice or from
clinically ill CD1 mice infected with RML prions were homogenized
at room temperature in 10 volumes of PBS (phosphate-bu¡ered sa-
line) containing 0.25% trypsin by successive passages through 16-, 18-
and 20-gauge needles. Trypsin digestion was stopped by the addition
of trypsin inhibitor. The homogenate was then centrifuged (800 rpm,
5 min) to remove debris and connective tissue (see Fig. 1, step A).
When PK digestion of membrane-bound PrP was performed (see
below) the brain homogenate was diluted to 1% (w/v) with PBS-con-
taining Triton X-100 and deoxycholate (DOC, 0.5% each), incubated
on ice for 10 min and cleared by a low-speed spin (1500 rpm, 10 min) to
obtain a post-nuclear supernatant (PNS). The PNS was diluted with
sarkosyl bu¡er (0.5% in PBS) and analyzed by the ¢lter retention
assay. Alternatively, the PNS was subjected to a high-speed centrifu-
gation (13 000 rpm, 20 min) and the pellet resuspended in sarkosyl
bu¡er prior to analysis by the ¢lter retention assay (see Fig. 1, step B1).
2.1.2. Bovine brain. Bovine brain stem tissue of a control and a
BSE-diagnosed animal was homogenized in 10 volumes Triton X-100/
DOC bu¡er. PNSs were prepared and ¢ltered through NC mem-
branes. Detection of PrP was carried out as described for the mouse
brain extracts (see below). For Western blotting analysis, the homo-
genates were digested with PK (100 Wg/ml, 1 h at 37‡C) or mock-
treated, the samples boiled in SDS sample bu¡er separated by SDS^
PAGE, followed by electrotransfer to NC and Western blotting [13].
2.1.3. Cultured cells. N2a and scrapie-infected mouse neuroblas-
toma (ScN2a) cells were grown in modi¢ed Eagle’s medium supple-
mented with antibiotics (1 U/ml penicillin G and 1 mg/ml streptomy-
cin) and 10% fetal calf serum. N2a cells are an immortalized
neuroblastoma cell line (ATCC No. CCl 131). ScN2a cells were estab-
lished by infecting N2a cells with an enriched preparation of prions
isolated from the brains of scrapie-ill mice infected with RML prions
[10]. For treatment with DOSPA ScN2a, cells cultivated for 4 days
were incubated for 16 h in DOSPA as described [14]. Trypsin treat-
ment of the cells (0.25% ¢nal) was carried out on the cell culture dish
maintained on ice. After complete detachment of the cells, digestion
was terminated by the addition of a 10-fold excess of soybean trypsin
inhibitor (Gibco BRL). The cells were collected by a brief centrifuga-
tion, washed twice with PBS-containing trypsin inhibitor and then
protein lysates were prepared as described for brain samples. An
equivalent of 106 cells was used for the ¢lter retention assay.
2.2. PK treatment
2.2.1. In homogenates. 10% homogenates were ¢rst incubated with
DNase I (Roche) (1 h, 37‡C) to eliminate high-molecular weight
DNA. Subsequently, PK (Roche) (100 Wg/ml) was added, the lysates
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incubated for 1 h at 37‡C, and proteolysis terminated by the addition
of Pefabloc (Roche). After a low-speed spin, the resultant supernatant
was analyzed for PrPSc (see Fig. 1, step B2).
2.2.2. On ¢lter. Membranes loaded with protein were submerged
in PK bu¡er (500 Wg/ml in PBS) for 30 min at room temperature. The
reaction was stopped by extensive washing (three times in PBST bu¡-
er (PBS, 0.1% Tween)) (see Fig. 1, step D).
2.3. Filter retention and immunodetection
A commercially available slot blot device (Amersham Pharmacia
Biotech, PR 648 Slot Blot Manifold) was used for the ¢ltration of
protein homogenates through NC (0.45 Wm pore size) or CA (0.2 Wm
pore size) membranes (Schleicher and Schuell, Dassel, Germany). All
homogenates were applied in duplicate and in a stepwise 10-fold di-
lution with sarkosyl bu¡er as the diluent. After the samples were
¢ltered through the membrane, each slot was washed with 500 Wl
sarkosyl bu¡er (see Fig. 1, step C). For immunodetection, the mem-
branes were incubated with 3 M guanidinium^HCl for 10 min, washed
three times in PBST, and PrP was detected by the anti-PrP antibody
A7 using the enhanced chemoluminescence (ECL) detection system
(Amersham Pharmacia Biotech) (see Fig. 1, step E).
3. Results
3.1. A ¢lter retention assay to detect PrPSc in
brain homogenates
A ¢lter retention assay was developed to monitor the pres-
ence of detergent-insoluble PrPSc aggregates in homogenates
of scrapie- or BSE-infected brains and in lysates of scrapie-
infected cultured cells. Alternative strategies were employed
for the preparation of protein extracts from scrapie-infected
mouse brains and the selective proteolysis of PrPC. These
variations of the procedure are outlined in the £ow diagram
of Fig. 1. Brie£y, whole mouse brains were homogenized in
Triton X-100/DOC detergent bu¡er by successive passages
through 16-, 18- and 20-gauge needles (Fig. 1, step A). Addi-
tion of trypsin during homogenization facilitated tissue disso-
ciation and degraded cell surface PrPC. After addition of tryp-
sin inhibitor, cell debris and connective tissue were removed
by centrifugation. The resulting supernatant was processed
either with or without PK treatment. Homogenate B1 (no
PK treatment) was subjected to low-speed centrifugation to
prepare a PNS. After addition of sarkosyl, this PNS was used
directly for analysis by ¢ltration. Alternatively, PrPSc aggre-
gates were ¢rst pelleted from the PNS and then resuspended
in sarkosyl bu¡er. Homogenate B2 (with PK treatment) was
incubated with DNase to eliminate high-molecular weight
DNA prior to incubation with PK. Filtration through CA
or NC membranes was performed with a commercially avail-
able slot blot device (step C). To minimize sample handling,
we also explored the possibility to degrade PrPC directly on
the ¢lter membrane after ¢ltration of the homogenates (step
D). PrPSc was detected by immunostaining after a brief incu-
Fig. 1. Flow chart of the ¢lter retention assay describing alternative
procedures for the detection of PrPSc in brain homogenates (see text
and Section 2 for details). In route B1, treatment with PK is per-
formed on the membranes (D), whereas in B2, incubation with PK
occurs in the lysates.
Fig. 2. Selective ¢lter retention of PrPSc from mouse brain homoge-
nates. A: 10% brain homogenates were processed as described to
obtain a PNS or a high-speed pellet fraction in sarkosyl bu¡er (Fig.
1, step B1). Serial dilutions were prepared in sarkosyl bu¡er and ap-
plied onto CA or NC ¢lters. Amounts of wet weight of brain tissue
analyzed are indicated in Wg. B: PNS from scrapie-infected brain
was diluted with nine volumes of PNS from control brain. The
amounts indicated refer to the wet weight of scrapie-infected brain
tissue present in the sample. Immunodetection was carried out after
PK digestion on the membrane (Fig. 1, step D) with the anti-PrP
antibody A7 and the ECL detection system.
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bation of the membranes in 3 M guanidinium^HCl to expose
PrP epitopes [9].
Fig. 2A shows a comparison of the PrPSc retention proper-
ties of CA (0.2 Wm pore size) and NC (0.45 Wm pore size)
membranes loaded with PNS or resuspended high-speed pel-
lets from scrapie-infected and control brains (see Fig. 1, step
B1). PK digestion was performed after ¢ltration directly on
the membranes (see Fig. 1D, step D). For both membranes
the assay was highly speci¢c for PrPSc in scrapie-infected mice
as no signal above background was detected with control
homogenates from non-infected animals. Analysis of serial
dilutions of the various preparations indicated that with
both membranes a clear signal was obtained with an amount
of homogenate corresponding to 150 Wg of wet weight of
brain tissue. Sensitivity and the signal to background ratio
were better for the NC membrane. To demonstrate that the
sensitivity of the ¢lter retention assay is una¡ected by the
total amount of tissue analyzed, homogenates of scrapie brain
were serially diluted with control homogenate, leaving the
total amount of protein constant. Again, the PrPSc present
in 100 Wg of scrapie brain homogenate, now analyzed in the
presence of 900 Wg of control homogenate, was clearly de-
tected by the ¢lter retention assay (Fig. 2B).
Homogenates treated with PK before ¢ltration (see Fig. 1,
step B2) were used to compare the sensitivity of the ¢lter
retention assay with the Western blotting procedure that is
frequently used for the routine detection of PrPSc (Fig.
3A,B). After PK digestion, equivalent amounts of homoge-
nates were either ¢ltered through a NC membrane (Fig. 3A)
or analyzed by SDS^PAGE and electrotransfered to the same
type of NC membrane (Fig. 3B). Immunodetection of PrP on
both membranes was done in parallel. Similar to the results
obtained with PK treatment after ¢ltration, an amount of
PrPSc derived from 150 Wg brain tissue was clearly detected
in the ¢lter retention assay and PrPSc from 15 Wg of tissue was
still weakly detectable (Fig. 3A, left panel). The assay gave an
essentially linear response between 15 Wg and 15 mg of scrapie
brain tissue. In contrast, the analysis of PrPSc by Western
blotting was at least 10-fold less sensitive (Fig. 3B, right pan-
el).
In summary, the ¢lter retention assay detects PrPSc in brain
homogenates of mice with experimental scrapie speci¢cally
and with high sensitivity. The laborious steps of SDS^
PAGE and immunoblotting can be omitted. PK treatment
of individual samples is circumvented, thus further minimizing
sample handling and avoiding a potential source of variabil-
ity.
3.2. Detection of PrPSc in the brain of preclinical BSE-infected
cattle
We tested whether the ¢lter retention assay for PrPSc can
also be used to detect BSE-infected cattle. Bovine brain stem
tissue from a diagnosed, preclinical animal was obtained from
Dr. M. Groschup (Federal Research Center for Virus Dis-
eases of Animals, Tu«bingen, Germany). The most rapid pro-
cedure for sample preparation outlined in Fig. 1 was chosen
for this analysis. Control and BSE-infected brain tissue was
directly homogenized in Triton X-100/DOC bu¡er. PNSs were
prepared and serial dilutions thereof were ¢ltered through a
NC membrane. Prior to immunodetection with the A7 anti-
PrP antiserum, membrane-bound proteins were subjected to
limited PK digestion. PrPSc was speci¢cally detected in sam-
ples derived from 100 Wg of BSE brain tissue (Fig. 4A).
To compare the sensitivity of the ¢lter retention assay with
Fig. 3. Detection of PrPSc in mouse brain by ¢lter retention assay and by SDS^PAGE/Western blotting. Brain homogenates were subjected to
PK treatment (Fig. 1, step B2) and serial dilutions analyzed in parallel by the ¢lter retention assay (A) and by SDS^PAGE and Western blot-
ting (B). PrP was detected as described in Fig. 2. Results were quanti¢ed by phosphorimager analysis (right panels).
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a Western blotting approach, 10% brain homogenates were
digested with PK (100 Wg/ml, 1 h at 37‡C), separated with
SDS^PAGE, and transferred to NC membranes. Immunode-
tection was done in parallel with the same type of NC ¢lter
used in the ¢lter assay approach. The BSE-infected sample
was clearly identi¢ed, however, with an at-least 10-fold re-
duced sensitivity compared to the ¢lter retention assay (Fig.
4B). Thus, the ¢lter retention assay is capable of detecting
PrPSc in brain stem tissue of cattle with preclinical BSE.
3.3. A screening method for anti-prion compounds
ScN2a cells o¡er the possibility to study the propagation of
PrPSc in cell culture [10^12]. We successfully used this cell
culture model to identify compounds that interfere with the
accumulation of PK-resistant and -infectious PrPSc [13^15].
Notably, the lipopolyamine DOSPA at nanomolar concentra-
tions induced degradation of pre-existing PrPSc aggregates in
live cells within 16 h [14]. In order to explore the possible use
of the ¢lter retention assay as a screening method for anti-
prion compounds, we adapted the sample preparation em-
ployed for brain tissue (see Fig. 1). Total cell lysates with
and without PK digestion, PNSs and high-speed pellets,
were prepared from an equal number of cells (Fig. 5A). A
positive signal for PrP was only obtained with lysates pre-
pared from ScN2a cells, indicative of the presence of PrPSc.
Next, ScN2a cells that had accumulated substantial
amounts of PrPSc were incubated for 16 h with increasing
nanomolar concentrations of DOSPA (Fig. 5B). As for brain
homogenates, low-speed supernatants and resuspended high-
speed pellets of cell lysates were analyzed by the ¢lter reten-
tion assay. With both methods a concentration-dependent de-
crease in the amounts of detectable PrPSc was observed, dem-
onstrating the suitability of the ¢lter retention assay as a
screening method for anti-prion compounds.
4. Discussion
The advent of new variant CJD suggests that prion diseases
can be transmitted from animals to humans [5,6,16^18]. To
eliminate scrapie-infected material from food and pharma-
ceutical products, a large number of domestic animals must
be tested for the presence of infectious prions. Currently avail-
able assays for the detection of PrPSc in brain samples utilize
the protease resistance of PrPSc relative to PrPC as the single
diagnostic criterion for PrPSc. Brain homogenates are incu-
bated with PK individually, a potential source of variability
and false-positive test results, and the remaining PrP protein is
detected immunologically by ELISA or by laborious SDS^
PAGE and Western blotting procedures. To avoid these prob-
lems, we have developed a simple ¢lter retention assay for
PrPSc that measures two diagnostic biochemical properties
of PrPSc in combination, protease resistance and the presence
of a detergent-insoluble aggregated state. PK treatment can be
performed conveniently and under standardized conditions
directly on the ¢lter membrane for many samples in parallel.
Providing various options for sample preparation, the ¢lter
retention assay is adaptable to di¡erent tissues and also to
liquor samples. Its main advantage is the concentration of
PrPSc from large sample volumes on a small ¢lter area, result-
ing in highly sensitive detection with very little or no back-
ground signal from normal PrPC. The PrPSc present in as little
Fig. 4. Detection of PrPSc in brain extracts of BSE-infected cattle.
A: Serial dilutions of PNS were ¢ltered onto NC membranes (0.45
Wm pore size) and membrane-bound proteins subjected to limited
PK digestion. B: 10% brain homogenates were mock-treated (-PK)
or incubated with PK (+PK), boiled in SDS sample bu¡er, sepa-
rated by SDS^PAGE and electrotransferred onto NC ¢lters (0.45
Wm). Immunodetection of membrane-bound PrP was carried out
with anti-PrP antiserum A7.
Fig. 5. A cell culture model for the screening of anti-prion com-
pounds. A: Detection of PrPSc from ScN2a cells. Protein lysates
from ScN2a and non-infected N2a cells were prepared, and PrP was
analyzed by ¢lter retention assay. B: DOSPA induces degradation
of PrPSc. ScN2a cells cultivated for 4 days were incubated in DOS-
PA (5 or 10 nM) or mock-treated (DOSPA, 0 nM) for an addition-
al 16 h. PNS and high-speed pellets were prepared and PrP ana-
lyzed by ¢lter retention assay. Immunodetection was carried out as
described in Fig. 2.
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as 100 Wg of wet weight of infected mouse or bovine brain can
be detected reliably. In contrast, upon SDS^PAGE and West-
ern blotting, the PrP signal spreads over a mass range from 27
to 30 kDa. This and the limited e⁄ciency of electrotransfer
may explain why in a side-by-side comparison, the perform-
ance of SDS^PAGE and Western blotting was inferior to that
of the ¢lter retention assay.
Another application of the ¢lter retention assay is the
screening of compound libraries for anti-prion agents. Proof
of principle was provided by the demonstration of the con-
centration-dependent e¡ect of the lipopolyamine DOSPA in
causing degradation of PrPSc in a cell culture model of ScN2a
cells [14]. We are currently adapting the cell culture assay to a
96-well format to establish a high-throughput screen for anti-
prion compounds.
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